Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women - Full Text View

Sponsor:	Depomed
Information provided by:	Depomed
ClinicalTrials.gov Identifier:	NCT00755417

Purpose

Depomed's Gabapentin Extended Release is an investigational, extended release formulation of gabapentin that is being studied for the treatment of hot flashes in postmenopausal women.

Condition	Intervention	Phase
Hot Flashes	Drug: Gabapentin Extended Release tablets	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Factorial Assignment, Safety/Efficacy Study
Official Title:	A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women

Resource links provided by NLM:

Drug Information available for: Gabapentin

U.S. FDA Resources

Further study details as provided by Depomed:

Primary Outcome Measures:

Reduction of frequency and severity of hot flashes after 24 weeks of treatment with a stable dose relative to placebo, compared with the baseline week. [ Time Frame: At 4 and 12 weeks of treatment ] [ Designated as safety issue: No ]

Estimated Enrollment:	540
Study Start Date:	September 2008
Study Completion Date:	October 2009
Primary Completion Date:	August 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental	Drug: Gabapentin Extended Release tablets Gabapentin Extended Release tablets
2: Experimental	Drug: Gabapentin Extended Release tablets Gabapentin Extended Release tablets

Detailed Description:

The primary study objective is to assess the efficacy of G-ER dosed in either of the following regimens:

G-ER 1200mg daily (single evening dose)
G-ER 1800mg daily (dosed asymmetrically; 600mg AM/1200mg PM) compared to placebo in reducing the average daily frequency and severity score of moderate to severe hot flashes in postmenopausal women after 4 weeks and 12 weeks of treatment with a stable dose, compared with the baseline week.

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Generally healthy, postmenopausal women who seek treatment for hot flashes.
Patients using hormone replacement therapy (HRT) must be willing to discontinue treatment.
Patients must be experiencing at least 7 moderate to severe hot flashes per day

Other Inclusions apply.

Exclusion Criteria:

Patients with hypersensitivity to gabapentin.
Patients with severe chronic diarrhea, chronic constipation, uncontrolled irritable bowel syndrome (IBS) or unexplained weight loss.
Patients treated with estrogen pellets or injectable progestin drug therapy within 6 months.

Other Exclusions apply.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00755417

Show 32 Study Locations

Sponsors and Collaborators

Depomed

More Information

No publications provided

Responsible Party:	Depomed ( Clinical Operations )
Study ID Numbers:	BREEZE 1, 81-0058
Study First Received:	September 17, 2008
Last Updated:	November 2, 2009
ClinicalTrials.gov Identifier:	NCT00755417 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Depomed:

Hot flashes
Hot flushes
Postmenopausal symptoms
Vasomotor symptoms

Additional relevant MeSH terms:

Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anti-Dyskinesia Agents
Gabapentin
Physiological Effects of Drugs
Hot Flashes
Psychotropic Drugs
Antiparkinson Agents
Calcium Channel Blockers
Excitatory Amino Acid Agents
Membrane Transport Modulators
Signs and Symptoms
Sensory System Agents

Therapeutic Uses
Analgesics
Excitatory Amino Acid Antagonists
Tranquilizing Agents
Central Nervous System Depressants
Cardiovascular Agents
Antimanic Agents
Pharmacologic Actions
Anti-Anxiety Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Anticonvulsants

ClinicalTrials.gov processed this record on February 08, 2010